Biomarkers of the Endocannabinoid System in Substance Use Disorders
Despite substance use disorders (SUD) being one of the leading causes of disability and mortality globally, available therapeutic approaches remain ineffective. The difficulty in accurately characterizing the neurobiological mechanisms involved with a purely qualitative diagnosis is an obstacle to i...
Main Authors: | Francisco Navarrete, María S. García-Gutiérrez, Ani Gasparyan, Daniela Navarro, Francisco López-Picón, Álvaro Morcuende, Teresa Femenía, Jorge Manzanares |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-03-01
|
Series: | Biomolecules |
Subjects: | |
Online Access: | https://www.mdpi.com/2218-273X/12/3/396 |
Similar Items
-
Endocannabinoid System Components as Potential Biomarkers in Psychiatry
by: Francisco Navarrete, et al.
Published: (2020-04-01) -
The Endocannabinoid System and Cannabidiol's Promise for the Treatment of Substance Use Disorder
by: Yann Chye, et al.
Published: (2019-02-01) -
Plasma endocannabinoid alterations in individuals with substance use disorder are dependent on the mirror effect of schizophrenia
by: Joelle eDesfossés, et al.
Published: (2012-09-01) -
CB2 Receptor Involvement in the Treatment of Substance Use Disorders
by: Francisco Navarrete, et al.
Published: (2021-10-01) -
Role of Cannabidiol in the Therapeutic Intervention for Substance Use Disorders
by: Francisco Navarrete, et al.
Published: (2021-05-01)